Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Diabetes treatment linked to increased blood pressure in animal study

11.07.2002

A report in the July issue of the Journal of Clinical Investigation has found that a group of drugs currently under development for the treatment of Type II diabetes caused both increased heart rate and elevated blood pressure in animal studies.

These new findings regarding glucagon-like peptide (GLP-1) receptor agonists suggest that the brain’s GLP-1 system has the ability to affect autonomic function, leading to changes in heart rate and blood pressure.

A naturally occurring hormone that is produced by cells lining the intestine, GLP-1 was first targeted as a diabetes treatment about 15 years ago, according to the study’s senior author Joel Elmquist, D.V.M., Ph.D., a neuroscientist and endocrinologist at Beth Israel Deaconess Medical Center and Associate Professor of Neurology and Medicine at Harvard Medical School.

"GLP-1 stimulates insulin secretion and controls feeding and drinking behavior, and also regulates neuroendocrine responses to agents that elicit illness-like behaviors," he explains. "The effect on insulin secretion made the hormone an obvious target for treating diabetes."

Diabetes develops when the body fails to either produce or to properly use insulin, a hormone necessary to convert food – including sugars and starches – into energy. Type II diabetes accounts for the majority of cases of the disease, and is a huge public health problem: As many as 16 million individuals in the United States have Type II diabetes, which puts them at risk for a number of serious complications, including stroke and heart disease.

Although diabetes can often be controlled through diet, exercise and existing medications, the magnitude of the problem has given rise to the development of a number of new drugs to better manage the disease, including the GLP-1 agonists. These agents, which are currently being tested in clinical trials, work by targeting the rate of gastric emptying and by stimulating insulin secretion from islet cells in the pancreas.

Circulating levels of the naturally occurring GLP-1 hormone in health individuals are low when the body is in a fasting state, according to Elmquist. After a person has eaten, GLP-1 levels rise, only to fall within minutes as a result of enzymatic activity. In fact, he adds, continuous infusion of GLP-1 does not increase either blood pressure or heart rate in humans with Type II diabetes.

However, in drug form, GLP-1 analogs such as EXENDIN-4 have a far more potent and long-lasting influence. In the studies on rodents conducted in Elmquist’s lab, the researchers demonstrated that EXENDIN-4 – which is being tested as a therapeutic agent – activated several key autonomic regulatory sites in the brain, leading to increased heart rate and blood pressure in the animals.

"Despite accumulating data linking GLP-1 to autonomic and neuroendocrine responses, the pathways [responsible] for the actions were previously not well understood," explains Elmquist. "Although these new findings in animals will need to be studied further, especially in diabetic models, this research suggests that the central GLP-1 system can regulate sympathetic outflow including raising heart rate and blood pressure."

###

Study co-authors include Beth Israel Deaconess researchers Hiroshi Yamamoto, M.D., Ph.D., Charlotte Lee, M.S., Jacob Marcus, B.S., Marisol Lopez, Ph.D., and Anthony Hollenberg, M.D.; Todd Williams, Ph.D., and J. Michael Overton, Ph.D., of Florida State University; and Laurie Baggio, Ph.D., and co-principal investigator Daniel Drucker, M.D., of the Banting and Best Diabetes Center at the University of Toronto.

The study was funded by grants from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institutes of Health.

Beth Israel Deaconess Medical Center is a major patient care, research and teaching affiliate of Harvard Medical School and a founding member of CareGroup Healthcare System. Beth Israel Deaconess is the third largest recipient of National Institutes of Health funding among independent U.S. teaching hospitals.

Bonnie Prescott | EurekAlert

More articles from Health and Medicine:

nachricht Fast-tracking T cell therapies with immune-mimicking biomaterials
16.01.2018 | Wyss Institute for Biologically Inspired Engineering at Harvard

nachricht Dengue takes low and slow approach to replication
12.01.2018 | Duke University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

White graphene makes ceramics multifunctional

16.01.2018 | Materials Sciences

Breaking bad metals with neutrons

16.01.2018 | Materials Sciences

ISFH-CalTeC is “designated test centre” for the confirmation of solar cell world records

16.01.2018 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>